Study Of Single Ascending Doses Of PBL 1427 In Healthy Volunteers
Status:
Unknown status
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
PBL 1427 is a Dipeptidyl peptidase (DPP)-IV inhibitor being developed for treatment of type 2
diabetes. Although a number of DPP-IV inhibitors have been described, there still exists a
need for new DPP-IV inhibitors that have better half-life, advantageous potency, stability
and selectivity, less toxicity and/or better pharmacodynamic properties.